Clinical Trial Update: EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating the combination of eribulin and pembrolizumab in patients with ovarian carcinosarcoma or uterine carcinosarcoma is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Carcinosarcoma
• Uterine Carcinosarcoma

Drugs mentioned

• Eribulin (eribulin mesilate)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: Australia New Zealand Gynaecological Oncology Group | Conditions: Ovarian Carcinosarcoma, Uterine Carcinosarcoma | Phase 2 | Status: RECRUITING